X4 Pharmaceuticals (NASDAQ:XFOR) Stock: Insider Adam Craig Acquires 4,600 Shares

Posted by Brian Himes on Oct 21st, 2026

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) Chairman Adam Craig bought 4,600 shares of the company’s stock in a transaction dated Friday, October 16th. The stock was bought at an average cost of $2.58 per share, with a total value of $11,868.00. Following the acquisition, the chairman directly owned 333,251 shares of the company’s stock, valued at approximately $859,787.58. The trade was a 1.40% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

X4 Pharmaceuticals Trading Up 9.8%

XFOR opened at $3.02 on Wednesday. The company’s 50 day moving average is $3.48 and its 200-day moving average is $3.87. X4 Pharmaceuticals, Inc. has a 1-year low of $2.43 and a 1-year high of $4.83. The company has a current ratio of 11.30, a quick ratio of 11.02 and a debt-to-equity ratio of 0.49. The company has a market cap of $299.42 million, a P/E ratio of -2.52 and a beta of 0.46.

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05. The company had revenue of $8.81 million for the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. Equities research analysts predict that X4 Pharmaceuticals, Inc. will post -0.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Pettinga Financial Advisors LLC acquired a new stake in X4 Pharmaceuticals during the 2nd quarter worth approximately $47,000. SummitTX Capital L.P. acquired a new position in X4 Pharmaceuticals in the 1st quarter valued at approximately $46,000. WINTON GROUP Ltd raised its stake in shares of X4 Pharmaceuticals by 35.8% during the second quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock valued at $67,000 after acquiring an additional 3,800 shares during the last quarter. AXQ Capital LP acquired a new position in shares of X4 Pharmaceuticals during the second quarter worth $107,000. Finally, Wellington Management Group LLP acquired a new position in shares of X4 Pharmaceuticals during the second quarter worth $242,000. Institutional investors own 72.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on XFOR. Weiss Ratings upgraded shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. Wells Fargo & Company initiated coverage on X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an “overweight” rating and a $11.00 price target for the company. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.25.

Get Our Latest Analysis on X4 Pharmaceuticals

About X4 Pharmaceuticals

(Get Free Report)

X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.